Peptide Evidence Tiers Explained: The S/A/B/C/D System (2026)

Not all peptide research is equal. Two compounds might each have '30 published studies' behind them — but 30 rat studies and 30 human RCTs are not remotely the same evidence. This is why the Bioactive Compounds library uses a five-tier evidence system: S / A / B / C / D. Every compound in our library — all 60 of them — carries one of these ratings, and understanding what they mean is the single most useful skill a research consumer can develop. This guide walks through the framework, gives examples at each tier, and explains the specific pitfalls we watch for when scoring evidence.

Why We Use a Tier System

Publication counts are a lazy proxy for evidence quality. A peptide with 200 preclinical papers and zero human RCTs is objectively less well understood in humans than a peptide with 5 large phase-3 trials.

The tier system solves three specific problems:

• Species translation: Rodent data does not automatically translate to humans. Dose-response curves, half-lives, and safety windows all shift.
• Study quality asymmetry: One well-conducted double-blind RCT carries more weight than a dozen open-label case series.
• Regulatory position: A peptide licensed for therapeutic use by the FDA/MHRA has cleared a bar that unapproved compounds have not.

Tiers do not tell you whether something 'works' — they tell you how confident we should be that it works, based on the current evidence base.

Tier S — FDA/EMA Approved for Human Therapeutic Use

Tier S compounds are licensed medicines with overwhelming human safety and efficacy data.

These are peptides that have cleared the same evidence bar as any pharmaceutical. Manufacturing, purity, and dosing are all standardised. The examples in our library:

• Semaglutide — GLP-1 agonist, approved for type 2 diabetes (Ozempic) and weight management (Wegovy)
• Tirzepatide — dual GLP-1/GIP agonist, approved for type 2 diabetes (Mounjaro) and weight (Zepbound)
• Tesamorelin — GHRH analogue, approved for HIV-associated lipodystrophy (Egrifta)
• Liraglutide — GLP-1 agonist, approved for diabetes and weight (Victoza/Saxenda)

What Tier S does NOT mean: It doesn't mean the compound is universally safe, appropriate for everyone, or without side effects. Semaglutide has real GI side effects and can cause gastroparesis. Tier S means the regulator has weighed benefits against risks and approved the compound for a specific indication.

Tier A — Strong Human RCT Data (Not Yet Approved)

Tier A compounds have multiple published human RCTs showing reproducible effects, but are not yet licensed.

These are the compounds a serious researcher takes seriously. The evidence base is closest to a licensed drug — sometimes the compound has finished phase-2 or is in phase-3 trials, but hasn't yet received regulatory approval, or has been approved outside the US/UK.

Examples from the library:

• Retatrutide — Eli Lilly's triple agonist, phase-3 (SURMOUNT-5 and TRIUMPH programs) with weight loss data exceeding tirzepatide
• Cagrilintide — amylin analogue in phase-3 combined with semaglutide (CagriSema)
• Bremelanotide — FDA-approved for HSDD in females (Vyleesi) — sits at S/A boundary depending on how you count

Tier A compounds carry high confidence that the effect is real; the remaining uncertainty is around long-term safety, optimal dosing, and how quickly regulators will move.

Tier B — Promising: Some Human Data + Strong Preclinical

Tier B compounds have at least one small human trial and consistent, well-mechanised animal data.

This is where a lot of the most interesting peptide research sits. The mechanism is well-understood, the animal data is robust and reproducible, and there's some human signal — but not enough independent RCTs to elevate the compound to Tier A.

Examples:

• TB-500 / Thymosin Beta-4 — extensive preclinical data on tissue repair, some human trials (particularly cardiac) — but not enough to reach Tier A
• Thymalin — decades of Russian clinical use with published data
• AOD-9604 — completed phase 2b human trials, results were mixed

Researchers here are betting on mechanism and preclinical strength. The primary risk is that the effect size in humans turns out smaller than the animal work suggested — a common historical pattern.

Tier C — Early / Mixed: Limited Human Trials

Tier C compounds have limited human data, mixed results, or important unresolved safety questions.

This is where the most famous 'wellness peptides' actually sit — a fact the online discourse rarely acknowledges.

• BPC-157 — despite its huge preclinical footprint, has minimal published human RCT data. The Zagreb group has published extensively in animals; human data is still catching up.
• GHK-Cu — strong topical cosmetic evidence; systemic effects are less well characterised in humans
• Melanotan II — real melanocortin agonist activity, but human safety data is limited and adverse events (rhabdomyolysis, melanoma reports) have been documented

Tier C is not a warning to avoid — it's a call for calibration. Researchers should be tracking their own biomarkers, using modest doses, and not assuming that preclinical effect sizes translate.

Tier D — Mostly Preclinical / Animal Data Only

Tier D compounds have compelling animal or in-vitro data but essentially no human trials.

Many of the 'newest' research peptides live here. This is not a criticism — every Tier S compound started at Tier D. But it means researchers should be honest with themselves about how much they actually know.

• MOTS-c — exciting mitochondrial-derived peptide with strong rodent data; human trials still very limited
• Humanin — 20+ years of mitochondrial biology research; almost no human clinical work
• SS-31 / Elamipretide — human trials underway (Barth syndrome) but broader effects mostly preclinical

The two questions we always apply to Tier D compounds: (1) is the mechanism plausible in humans given known biology? (2) is there any safety signal from the preclinical work that would make first-in-human dosing risky?

Common Mistakes in Reading Evidence

Even seasoned researchers fall for the same pitfalls — count-of-studies, mechanism-only reasoning, and the fallacy of open-label enthusiasm.

Three specific things to watch for:

1. The publication-count trap. 'BPC-157 has hundreds of studies' — most of those are in rodents from the same handful of labs. Volume ≠ evidence quality.
2. Mechanism-only reasoning. 'This peptide activates AMPK, therefore it will do X in humans.' Cellular mechanism does not automatically imply organism-level clinical benefit at achievable doses.
3. Open-label enthusiasm. Small open-label trials in motivated researcher-users have huge placebo/expectancy effects. Blinded, controlled data is the only way to isolate the compound's effect.

The tier system tries to encode these considerations. If a compound has 30 studies but they're all from the same group in the same species, it stays Tier D no matter how impressive individual papers look.

How to Actually Use Tiers in Your Research

Match your tier tolerance to your goals. Tier S/A for anything you're doing indefinitely; Tier B/C for time-limited investigation; Tier D only with rigorous self-tracking.

A practical framework:

• Chronic use (months–years): Stick to Tier S/A. The long-term safety data simply doesn't exist for lower tiers.
• Short protocol (4–12 weeks) targeting a specific goal: Tier B is reasonable — you have some human data, and you can measure baseline vs. endpoint biomarkers.
• Exploratory (a few weeks, structured self-experiment): Tier C requires you to have a plan for what you'll measure and when you'll stop.
• Tier D: Only with rigorous bloodwork tracking, ideally under research-protocol conditions, and never as your only intervention.

The tier isn't a scorecard — it's a calibration tool for the level of uncertainty you're accepting.

Frequently Asked Questions